Umeclidinium Bromide
Brand name: Incruse Ellipta
Rank #128 of 500 drugs by total cost
$131.6M
Total Cost
290,677
Total Claims
$131.6M
Total Cost
11,376
Prescribers
$453
Cost per Claim
21,789
Beneficiaries
362,254
30-Day Fills
$12K
Avg Cost/Provider
26
Avg Claims/Provider
About Umeclidinium Bromide
Umeclidinium Bromide (sold as Incruse Ellipta) was prescribed 290,677 times by 11,376 Medicare Part D providers in 2023, costing the program $131.6M. At $453 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 125 | Buprenorphine Hcl/Naloxone Hcl (Buprenorphine-Naloxone) | $135.8M | 696,008 |
| 126 | Cenegermin-Bkbj (Oxervate) | $133.5M | 3,601 |
| 127 | Teriflunomide (Aubagio) | $131.9M | 18,010 |
| 128 | Umeclidinium Bromide (Incruse Ellipta) | $131.6M | 290,677 |
| 129 | Tiotropium Br/Olodaterol Hcl (Stiolto Respimat) | $130.3M | 201,233 |
| 130 | Immun Globg(Igg)/Malt/Iga Ov50 (Octagam) | $129.5M | 9,657 |
| 131 | Pregabalin (Pregabalin) | $124.3M | 2,696,923 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology